Patients with psoriasis (PSO) and psoriatic arthritis (PsA) may need to switch biologic therapies throughout the course of treatment for various reasons.

Factors that influence biologic switching among patients with PSO and PsA remain unclear.

The objectives of this study were to evaluate the association of jointly measured psoriatic disease severity (e.g., Psoriasis Area Severity Index [PASI]) and patient-centered outcomes (e.g., Dermatology Life Quality Index [DLQI]) with biologic switch status among patients with PSO and PsA and to describe patient characteristics at initiation among those who switched or did not switch biologic therapies.

In this analysis of PSO patients with PsA treated in a real-world dermatology setting, measures related to disease factors were more severe among patients who switched biologic therapies.

Patient-centered factors should be considered as potential targets for clinical interventions intended to optimize treatment strategies for patients with PSO and PsA.